BDSI: Collegium Pharma acquires Biodelivery Sciences International Inc., and with it Belbuca , Symproic and Elyxyb.
Collegium Pharmaceutical, Inc. and Biodelivery Sciences International, Inc. announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.
Read full article »
BDSI is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions.
Read more